Toshiya Inaba

Last Updated :2017/09/01

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, ., Professor
E-mail
tinabahiroshima-u.ac.jp

Basic Information

Academic Degrees

  • M.D., The University of Tokyo

Research Fields

  • Medicine,dentistry, and pharmacy;Basic medicine;General medical chemistry
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Hematology

Educational Activity

Course in Charge

  1. 2017, Undergraduate Education, First Semester, Radiation Biology & Radiation Health Risk Sciences
  2. 2017, Undergraduate Education, Intensive, Practice for medical research
  3. 2017, Graduate Education (Master's Program) , First Semester, Molecular Biology and Radiological Science
  4. 2017, Graduate Education (Doctoral Program) , First Semester, Integrated radiation medical science
  5. 2017, Graduate Education (Doctoral Program) , First Semester, Integrated radiation medical science
  6. 2017, Graduate Education (Doctoral Program) , First Semester, Integrated radiation medical science
  7. 2017, Graduate Education (Doctoral Program) , First Semester, Integrated radiation medical science
  8. 2017, Graduate Education (Master's Program) , First Semester, Seminar on Molecular Oncology
  9. 2017, Graduate Education (Master's Program) , Second Semester, Seminar on Molecular Oncology
  10. 2017, Graduate Education (Master's Program) , First Semester, Research on Molecular Oncology
  11. 2017, Graduate Education (Master's Program) , Second Semester, Research on Molecular Oncology
  12. 2017, Graduate Education (Doctoral Program) , First Semester, Advanced seminar on Molecular Oncology
  13. 2017, Graduate Education (Doctoral Program) , Second Semester, Advanced seminar on Molecular Oncology
  14. 2017, Graduate Education (Doctoral Program) , First Semester, Advanced research on Molecular Oncology
  15. 2017, Graduate Education (Doctoral Program) , Second Semester, Advanced research on Molecular Oncology

Research Activities

Academic Papers

  1. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors, LEUKEMIA, 26(12), 2483-2493, DEC 2012
  2. Identification of the integrin beta 3 L718P mutation in a pedigree with autosomal dominant thrombocytopenia with anisocytosis, BRITISH JOURNAL OF HAEMATOLOGY, 160(4), 521-529, FEB 2013
  3. Reversal of Apoptosis by the leukemia-associated E2A-HLF Chimeric transcription factor, Nature, 382, 541, 19960401
  4. DNA binding specificity and trans-activating potential of the leukemia-associated E2A-HLF fusion protein, Molecular and Cellular Biology, 14, 3403, 19940401
  5. Genomic organization, chromosome localization, and independent expression of human cyclin D genes., Genomics, 13, 565-574, 19920401
  6. Functional and molecular characteristics of acute lymphoblastic leukemia cells with a mature T-cell phenotype from a patient with ataxia telangiectasia., Leukemia, 5, 88-89, 19920401
  7. Molecular analysis of bcr/abl products in a case of myelodysplastic syndrome with late appearing Philadelphia chromosome., Br J Haematol, 78, 130-132, 19910401
  8. Characterization of an embryonal rhabdomyosarcoma cell line showing amplification and over-expression of the N-myc oncogene., Int J Cancer, 705-711, 19900401
  9. Karyotypic patterns of acute mixed lineage leukemia., Leukemia, 4, 121-126, 19900401
  10. Heterogeneity in the breakpoints of chromosome 19 among acute leukemic patients with the t(11;19)(q23;p13) tranlocation., Am. J. Hematol. =, 31, 253-257, 19890401
  11. Fatal infectious mononucleosis with staphylococcal pyoderma in a girl with hereditary immunological dysregulations., Eur J Pediatr, 149, 177-178, 19890401
  12. Similar chromosomal patterns and lack of N-myc gene amplification localized and IV-S stage neuroblastoma in infants., Med. Pedatr. Oncol., 17, 111-115, 19890401
  13. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1., Cancer, 63, 126-132, 19890401
  14. The e2a-hlf oncoprotein activates groucho-related genes and suppresses runx1., Mol. Cell. Biol., 21, 5935-5945, 20010401
  15. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway., Kidney Int., 58, 269-282, 20000401
  16. Involvement of mTOR/Bim, not Akt/Bad pathway in cytokine-mediated cells survival signaling downstream of PI3-kinase in murine hematopoietic progenitors., Blood 96 Suppl., 1, 568A, 20000401
  17. Expression of E2A-HLF chimeric protein induced T-cell apoptosis, B-cell maturation arrest and development of acute lymphoblastic leukemia., Blood, 93, 2780-2790, 19990401
  18. Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3(E4BP4) and Bcl-xL, regulate the survival of murine pro-B lymphocytes., Mol. Cell. Biol., 19, 2754-2762, 19990401
  19. SLUG, a ces-1-related zinc-finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein., Mol. Cell, 4, 343-352, 19990401
  20. Expression patterns of the hepatic leukemia factor gene in the nervous system of developing and adult mice., Brain Res., 820, 1-11, 19990401
  21. Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation., Oncogene, 18, 165-172, 19990401
  22. Two candidate downstream target genes for E2A-HLF., Blood, 93, 321-332, 19990401
  23. Essential role of the BH3 factor, Bim, in the cytokine-mediated apoptosis program: Implications in the antiapoptotic Ras pathways and in leukemogenesis., Blood 94 Suppl., 1, 688A, 19990401
  24. Thyrotroph embryonic factor is a possible regulatory factor maintaining the quiscent hematopoietic progenitors., Blood 94 Suppl., 1, 271A, 19990401
  25. The AD1 and AD2 transactivation domains of E2A are essential for the antiapoptotic activity of the E2A-HLF chimeric oncoprotein., Mol. Cell. Biol., 18, 6035-6043, 19980401
  26. Transcription factor NF-E2 is essential for the polyploidization of a human megakaryoblastic cell line, Meg-J., Biochem. Biophys. Res. Commun., 247, 65-69, 19980401
  27. Involvement of Bim, the BH3-containing cell death activator, in cytokine-mediated apoptosis program and in leukemogenesis by the E2A-HLF chimera, Blood 92 Suppl., 1, 199A, 19980401
  28. Identification of the antiapoptotic zinc-finger transcription factor SLUG as a target of E2A-HLF oncogenic fusion protein., Blood 92 Suppl., 1, 479A, 19980401
  29. Groucho-related genes are activated by the E2A-HLF chimeric oncoprotein In FL5.12 cells., Blood 92 Suppl., 1, 589A, 19980401
  30. Downstream target genes for E2A-HLF Identified by cDNA microarray analysis., Blood 92 Suppl., 1, 590A, 19980401
  31. Development of a novel selective amplifier gene for controllable expansion of transduced hematopoietic cells., Blood, 90, 3884-3892, 19970401
  32. Pivotal role for the NFIL3/E4BP4 transcription factor in IL-3-mediated survival of pro-B lymphocytes., Proc. Natl. Acad. Sci. USA, 94, 2609-2614, 19970401
  33. Cell transformation mediated by homodimeric E2A-HLF transcription factors., Mol. Cell. Biology, 17, 1417-1424, 19970401
  34. Ras-dependent and -independent regulation of E4BP4/NFIL3 transcription factor in cytokine-mediated cell survival of pro-B lymphocytes: the target gene program for oncogenic Ras, Bcr-Abl and E2A-HLF chimeras in leukemogenesis., Blood 90 Suppl., 1, 47A, 19970401
  35. Thyrotroph embryonic factor (TEF) is capable of regulating the cell cycle and cell survival of lymphoid cells., Blood 90 Suppl., 1, 138A, 19970401
  36. Anti-apoptotic effects of E2A-HLF: Evidence for mechanisms involving both gain and loss of function., Blood 88(10) Supple., 1(10), 552A, 19960401
  37. E4BP4, an IL-3-responsive bZIP transcription factor, contributes to cell survival in mouse pro-B cells., Blood 88(10) Supple., 1(10), 658A, 19960401
  38. E2A-HLF-mediated cell transformation requires both the trans-activation domains of E2A and the leucine zipper dimerization domain of HLF., Mol. Cell. Biology, 15, 3247-3255, 19950401
  39. The E2A-HLF fusion protein as a direct hmodimeric trans-activator of downstream target genes in malignant transformation., abstr. Blood 86(10) Supple., 1(10), 39A, 19950401
  40. The oncogenc E2A-HLF fusion protein protects leukemic B-precursor cells from apotosis., abstr. Blood 86(10) Supple., 1(10), 327A, 19950401
  41. Chromosomal localization and cDNA cloning of the human DBP and TEF genes., Genomics, 23, 344-351, 19940401
  42. Differential molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia., Blood, 79, 1781-1785, 19920401
  43. Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines., Int J Cancer, 50, 977-983, 19920401
  44. Chromosome findings and prognosis in 15 patients with neuroblastoma found by VMA mass screening., J. Pediatr., 112, 567-571, 19880401
  45. Translocation 2;8 in a congenital rhabdomyosarcoma., Cancer Genet.Cytogenet., 30, 343-345, 19880401
  46. Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator, Gene Therapy, 10(5), 375-385, 20030301
  47. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors., Mol. Cell. Biol., 21, 854-864, 20010501
  48. The expression of Bcl-2 family proteins (Bcl-2, Bcl-x, Bax, Bak and Bim) in human lymphocytes., Immunol Lett, 81, 107-113, 20020501
  49. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome / acute myeloid leukemia., Blood, 101, 673-680, 20030501
  50. Regulation of osteoclast apoptosis by ubiqutination of proapoptotic BH3-only Bcl-2 family member Bim., EMBO J., 22, 6653-6664, 20030501
  51. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia., Blood, 103, 2316-2324, 20041001
  52. Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein., Blood, 103, 3185-3191, 20041001
  53. Deletion 6p23 and add(11)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia., Cancer Genet. Cytogenet., 152, 56-60, 20041001
  54. The Adenovirus E1A and E1B19K genes provide a helper function for transfection-based AAV vector production., J. Gen.Virol., 85, 2009-2014, 20041001
  55. TEF, an anti-apoptotic bZIP transcription factor related to the oncogenic E2A-HLF chimera, inhibits cell growth by downregulating expression of the common b chain of cytokine receptors., Blood, 105, 4437-4444, 20051001
  56. Structure of the human Bim gene and its transcriptional regulation in Baf-3, interleukin-3-dependent hematopoietic cells., Mol. Biol. Rep., 32, 79-85, 20051001
  57. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells., Brain Res., 1050, 15-26, 20051001
  58. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations., Leukemia, 20, 635-644, 20061001
  59. Cytokines direct the regulation of Bim mRNA stability by Heat shock cognate protein 70., Mol. Cell, 25, 99-112, 20071001
  60. Hypercalcemia in childhood acute lymphoblastic leukemia:frequent implication of PTHrP and E2A-HLF from translocation 17;19., Leukemia, 21, 288-296, 20071001
  61. Hyperactivation of the RAS signaling pathway in myelodysplastic syndromewith AML1/RUNX1 point mutations., Leukemia, 20, 635-644, 20061001
  62. Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors, MOLECULAR AND CELLULAR BIOLOGY, 21(3), 854-864, FEB 2001
  63. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBP alpha gene, GENES CHROMOSOMES & CANCER, 36(2), 167-174, FEB 2003
  64. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia, BLOOD, 101(2), 673-680, JAN 15 2003
  65. Enhancement of thymidine kinase-mediated killing of malignant glioma by BimS, a BH3-only cell death activator, GENE THERAPY, 10(5), 375-385, MAR 2003
  66. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim, EMBO JOURNAL, 22(24), 6653-6664, DEC 15 2003
  67. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia, BLOOD, 103(6), 2316-2324, MAR 15 2004
  68. Regulation of annexin II by cytokine-initiated signaling pathways and E2A-HLF oncoprotein, BLOOD, 103(8), 3185-3191, APR 15 2004
  69. Deletion 6p23 and add(II)(p15) leading to NUP98 translocation in a case of therapy-related atypical chronic myelocytic leukemia transforming to acute myelocytic leukemia, CANCER GENETICS AND CYTOGENETICS, 152(1), 56-60, JUL 1 2004
  70. Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors, MOLECULAR AND CELLULAR BIOLOGY, 24(14), 6172-6183, JUL 2004
  71. The adenovirus E1A and E1B19K genes provide a helper function for transfection-based adeno-associated virus vector production, JOURNAL OF GENERAL VIROLOGY, 85, 2209-2214, AUG 2004
  72. TEF, an antiapoptotic bZIP transcription factor related to the oncogenic E2A-HLF chimera, inhibits cell growth by down-regulating expression of the common beta chain of cytokine receptors, BLOOD, 105(11), 4437-4444, JUN 1 2005
  73. Structure of the human Bim gene and its transcriptional regulation in Baf-3, interleukin-3-dependent hematopoietic cells, MOLECULAR BIOLOGY REPORTS, 32(2), 79-85, JUN 2005
  74. Neuroprotective effects of erythropoietin on glutamate and nitric oxide toxicity in primary cultured retinal ganglion cells, BRAIN RESEARCH, 1050(1-2), 15-26, JUL 19 2005
  75. Nuclear abnormalities in aspirated thyroid cells and chromosome aberrations in lymphocytes of residents near the Semipalatinsk Nuclear Test Site, JOURNAL OF RADIATION RESEARCH, 47, A171-A177, FEB 2006
  76. Protein kinase B/Akt signalling is required for palmitate-induced beta-cell lipotoxicity, DIABETES OBESITY & METABOLISM, 8(2), 228-233, MAR 2006
  77. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations, LEUKEMIA, 20(4), 635-644, APR 2006
  78. Unstable-type chromosome aberrations in lymphocytes from individuals living near Semipalatinsk Nuclear Test Site, JOURNAL OF RADIATION RESEARCH, 47, A159-A164, FEB 2006
  79. Cytokines direct the regulation of Bim mRNA stability by heat-shock cognate protein 70, MOLECULAR CELL, 25(1), 99-112, JAN 12 2007
  80. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19, LEUKEMIA, 21(2), 288-296, FEB 2007
  81. AML1 mutations induced MDS and MDS/AML in a mouse BMT model, BLOOD, 111(8), 4297-4308, APR 15 2008
  82. Peptidoglycan and lipopolysaccharide activate PLC gamma 2, leading to enhanced cytokine production in macrophages and dendritic cells, GENES TO CELLS, 13(2), 199-208, FEB 2008
  83. Ras-mediated up-regulation of survivin expression in cytokine-dependent murine pro-B lymphocytic cells, TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 216(1), 25-34, SEP 2008
  84. Haploinsufficiency and acquired loss of Bcl11b and H2AX induces blast crisis of chronic myelogenous leukemia in a transgenic mouse model, CANCER SCIENCE, 100(7), 1219-1226, JUL 2009
  85. Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 383(2), 245-251, MAY 29 2009
  86. Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19), BLOOD, 116(6), 962-970, AUG 12 2010
  87. A 5 ' untranslated region containing the IRES element in the Runx1 gene is required for angiogenesis, hematopoiesis and leukemogenesis in a knock-in mouse model, DEVELOPMENTAL BIOLOGY, 345(2), 226-236, SEP 15 2010
  88. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54(3), 781-788, SEP 2011
  89. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma, BRITISH JOURNAL OF CANCER, 104(1), 91-100, JAN 4 2011
  90. The Dynactin Complex Maintains the Integrity of Metaphasic Centrosomes to Ensure Transition to Anaphase, JOURNAL OF BIOLOGICAL CHEMISTRY, 286(7), 5589-5598, FEB 18 2011
  91. The Samd9L Gene: Transcriptional Regulation and Tissue-Specific Expression in Mouse Development, JOURNAL OF INVESTIGATIVE DERMATOLOGY, 131(7), 1428-1434, JUL 2011
  92. A Modified System for Analyzing Ionizing Radiation-Induced Chromosome Abnormalities, RADIATION RESEARCH, 177(5), 533-538, MAY 2012
  93. Mouse Samd9l is not a functional paralogue of the human SAMD9, the gene mutated in normophosphataemic familial tumoral calcinosis, EXPERIMENTAL DERMATOLOGY, 21(7), 554-556, JUL 2012
  94. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62(7), 1055-1061, JUL 2013
  95. Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias, LEUKEMIA RESEARCH, 37(1), 93-101, JAN 2013
  96. Role of Pin1 Protein in the Pathogenesis of Nonalcoholic Steatohepatitis in a Rodent Model, JOURNAL OF BIOLOGICAL CHEMISTRY, 287(53), 44526-44535, DEC 28 2012
  97. Haploinsufficiency of SAMD9L, an Endosome Fusion Facilitator, Causes Myeloid Malignancies in Mice Mimicking Human Diseases with Monosomy 7, CANCER CELL, 24(3), 305-317, SEP 9 2013
  98. Acquired Deficiency of A20 Results in Rapid Apoptosis, Systemic Inflammation, and Abnormal Hematopoietic Stem Cell Function, PLOS ONE, 9(1), JAN 31 2014
  99. MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters, NUCLEIC ACIDS RESEARCH, 42(7), 4241-4256, APR 2014
  100. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation, NATURE COMMUNICATIONS, 5, JUN 2014
  101. AS-2, a novel inhibitor of p53-dependent apoptosis, prevents apoptotic mitochondrial dysfunction in a transcription-independent manner and protects mice from a lethal dose of ionizing radiation, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 450(4), 1498-1504, AUG 8 2014
  102. A Novel ATM/TP53/p21-Mediated Checkpoint Only Activated by Chronic gamma-Irradiation, PLOS ONE, 9(8), AUG 5 2014
  103. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22(2), 158-165, FEB 2015
  104. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS, LEUKEMIA, 29(4), 847-857, APR 2015
  105. -7/7q-syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity, ONCOGENE, 34(19), 2413-2425, MAY 7 2015
  106. Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2, BLOOD, 125(22), 3437-3446, MAY 28 2015
  107. Involvement of resistin-like molecule beta in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice, SCIENTIFIC REPORTS, 6, JAN 28 2016